Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Pediatric Risk Factors for Candidemia Secondary to Candida glabrata and Candida krusei Species.

Prasad PA, Fisher BT, Coffin SE, Walsh TJ, McGowan KL, Gross R, Zaoutis TE.

J Pediatric Infect Dis Soc. 2013 Sep;2(3):263-6. doi: 10.1093/jpids/pis093. Epub 2012 Oct 30.

2.

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG.

Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60.

3.

Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.

Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, Sorrell TC.

Crit Care Med. 2008 Jul;36(7):2034-9. doi: 10.1097/CCM.0b013e3181760f42.

PMID:
18552700
4.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
5.

Risk factors for fluconazole-resistant candidemia.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C.

Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54. doi: 10.1128/AAC.00479-10. Epub 2010 May 24.

6.

The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.

Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I.

Cancer. 2008 Jun;112(11):2493-9. doi: 10.1002/cncr.23466.

7.

Blood stream infections by Candida glabrata and Candida krusei: a single-center experience.

Choi HK, Jeong SJ, Lee HS, Chin BS, Choi SH, Han SH, Kim MS, Kim CO, Choi JY, Song YG, Kim JM.

Korean J Intern Med. 2009 Sep;24(3):263-9. doi: 10.3904/kjim.2009.24.3.263. Epub 2009 Aug 26.

8.

Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil.

Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, de Oliveira Cardoso LG, Schreiber AZ.

Med Mycol. 2013 Apr;51(3):225-30. doi: 10.3109/13693786.2012.708107. Epub 2012 Aug 27.

PMID:
22920712
9.

Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil.

Aquino VR, Lunardi LW, Goldani LZ, Barth AL.

Braz J Infect Dis. 2005 Oct;9(5):411-8. Epub 2006 Jan 6.

10.

Characteristics and risk factors of candidemia in pediatric intensive care unit of a tertiary care children's hospital in Egypt.

Hegazi M, Abdelkader A, Zaki M, El-Deek B.

J Infect Dev Ctries. 2014 May 14;8(5):624-34. doi: 10.3855/jidc.4186.

11.

[Clinical pathogenesis of candidemia caused by non-albicans Candida species].

Myoken Y.

Nihon Ishinkin Gakkai Zasshi. 2009;50(4):225-8. Review. Japanese.

12.

Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group.

Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.

13.

Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study.

Zilberberg M, Yu HT, Chaudhari P, Emons MF, Khandelwal N, Shorr AF.

Crit Care. 2014 Oct 29;18(5):590. doi: 10.1186/s13054-014-0590-1.

14.

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.

Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP.

Medicine (Baltimore). 2003 Sep;82(5):309-21.

15.

Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.

Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):919-27.

PMID:
17286303
16.

Global trends in the distribution of Candida species causing candidemia.

Guinea J.

Clin Microbiol Infect. 2014 Jun;20 Suppl 6:5-10. doi: 10.1111/1469-0691.12539. Epub 2014 Mar 6. Review.

17.

Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.

Tadec L, Talarmin JP, Gastinne T, Bretonnière C, Miegeville M, Le Pape P, Morio F.

Mycoses. 2016 May;59(5):296-303. doi: 10.1111/myc.12470. Epub 2016 Jan 25.

PMID:
26806101
18.

Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.

Quindós G, Sánchez-Vargas LO, Villar-Vidal M, Eraso E, Alkorta M, Hernández-Almaraz JL.

Int J Antimicrob Agents. 2008 Mar;31(3):266-71. Epub 2007 Dec 3.

PMID:
18054468
19.

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.

Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II.

Am J Med. 2002 Apr 1;112(5):380-5.

PMID:
11904112
20.

[Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].

Durán MT, Velasco D, Canle D, Moure R, Villanueva R.

Enferm Infecc Microbiol Clin. 2003 Nov;21(9):488-92. Spanish.

PMID:
14572381

Supplemental Content

Support Center